Results 41 to 50 of about 101 (70)

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. [PDF]

Clin Mol Hepatol
Cho YK, Jung CH.
europepmc   +1 more source

MASH and the race for liver antifibrotics. [PDF]

Front Gastroenterol (Lausanne)
Wills Q.
europepmc   +1 more source

Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions. [PDF]

Pharmaceutics
Dinkov B, Koleva N, Stavreva G.
europepmc   +1 more source

A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways. [PDF]

Front Endocrinol (Lausanne)
Park C, Kim Y, Raygani S, Grunvald E.
europepmc   +1 more source

The Obesity Drug Revolution: New Frontiers in Pharmacotherapy. [PDF]

Cureus
Manoria PC.
europepmc   +1 more source

Paradigm shift in obesity treatment: an extensive review of current pipeline agents. [PDF]

Turk J Med Sci
Çetin E, Pedersen B, Burak MF.
europepmc   +1 more source

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. [PDF]

Cureus
Patel JP, Hardaswani D, Patel J, Saiyed F, Goswami RJ, Saiyed TI, Patel H, Amin TH.   +7 more
europepmc   +1 more source

Innovative Glucagon-based Therapies for Obesity. [PDF]

J Endocr Soc
Enyew Belay K, Jemal RH, Tuyizere A.
europepmc   +1 more source

Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro-con debate. [PDF]

Eur Respir Rev
Patel SR, Ryan S.
europepmc   +1 more source

Evaluating the benefits of the early use of GLP-1 receptor agonists. [PDF]

Lancet
Zushin PH, Wu JC.
europepmc   +1 more source